A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs

​ Conditions: Tumor Patients Interventions: Drug: Trilaciclib and Topoisomerase I inhibitor type ADC drugs Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting Conditions: Tumor Patients Interventions: Drug: Trilaciclib and...